Načítá se...
Feasibility and attractiveness of indication value-based pricing in key EU countries
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use...
Uloženo v:
| Vydáno v: | J Mark Access Health Policy |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Co-Action Publishing
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4864834/ https://ncbi.nlm.nih.gov/pubmed/27226845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v4.30970 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|